MRI with hyperpolarized pyruvate in gliblastoma - a phase II study

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515408-37-00

Enrollment

Registered

2024-07-10

Start date

2020-04-01

Completion date

Unknown

Last updated

2025-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glioblastoma multiforme, cancer

Brief summary

[1-13C]pyruvate perfusion, uptake and conversion to [1-13C]lactate, [1-13C]alanine and [13C] bicarbonate in normal brain and tumor tissue

Detailed description

Perfusion (DCE MRI), Microvascular diffusion (ADC MRI), Amide proton transfer weight (APT) imaging, Progression-free survival (PFS), Overall survival (OS), Radiation dose distribution

Interventions

DRUGHyperpolarized [1-13C]pyruvate

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
[1-13C]pyruvate perfusion, uptake and conversion to [1-13C]lactate, [1-13C]alanine and [13C] bicarbonate in normal brain and tumor tissue	—

Secondary

Measure	Time frame
Perfusion (DCE MRI), Microvascular diffusion (ADC MRI), Amide proton transfer weight (APT) imaging, Progression-free survival (PFS), Overall survival (OS), Radiation dose distribution	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026